Drug Res (Stuttg) 2021; 71(02): 73-82
DOI: 10.1055/a-1286-5358
Original Article

Assessment of the Genotoxic Potential of Cizolirtine a Substance-P and Calcitonin Gene-Related Peptide Release Modulator

1   Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain
,
Ana-Paz Marín
1   Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain
,
Araceli Tortajada
1   Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain
,
Cristina Vila
1   Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain
,
Antonio Guzmán
1   Department of Toxicology, ESTEVE Pharamaceuticals, Barcelona and Department of Toxicology, WELAB, Barcelona, Spain
› Author Affiliations

Abstract

The analysis of the genotoxic potential of cizolirtine, a compound being developed as a drug for analgesia and for urinary incontinence, was carried out using a battery of in vitro and in vivo assays as recommended in the guidelines for medicinal products. Negative results were obtained in an Ames test (up to 5000 µg/plate), in a Mouse Lymphoma assay (up to 2000 µg/ml) and in a single dose mouse bone marrow micronucleus assay (up to 300 mg/kg). In a human lymphocyte chromosome aberration assay, a slight statistical increase in the frequency of cells with chromosome aberrations including gaps was reported for the concentrations of 200 and 1600 μg/ml at the 24-h sampling time. This minor increase in chromosome aberrations was considered of questionable biological relevance since it was moderate, was within the laboratory historical control values, did no show a dose-dependent effect and was not observed at similar concentrations in a repeat assay. Taking into considerations the results obtained in the different in vitro and in vivo assays and a weight-of-evidence analysis, it suggests that cizolirtine would not pose a genotoxic risk when administered to humans.



Publication History

Received: 02 July 2020

Accepted: 05 October 2020

Article published online:
04 November 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany